Developer docs
API playgroundTry for free, no card

Search company profiles

GlyTherix Ltd.

Full company profile

uuid000lwdm

Namestring
GlyTherix Ltd.
Websiteurl
glytherix.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

GlyTherix Ltd. is an Australian private biotechnology company focused on targeted radiotherapy, headquartered in Sydney and founded in 2017. The company operates in the radiopharmaceutical space, which typically involves the development of biological targeting agents (such as antibodies or small molecules) conjugated to therapeutic radioisotopes designed to deliver localized radiation to cancer cells while sparing healthy tissue. The firm's strategic positioning is consistent with the broader global shift toward precision oncology and theranostics, though the specific molecular targets, radioisotopes, and indication areas are not disclosed in the available source data.

The company is small-scale, with 1–10 employees per the firmographic data, and operates as a privately held for-profit entity. Brad Walsh is identified as Chief Executive Officer. There is no disclosed product portfolio, pricing model, manufacturing capability, clinical pipeline, regulatory filing status, or partnership structure in the provided inputs. The company website (glytherix.com) was not accessible for content extraction at the time of data collection, which itself limits the verification surface for the company's claims.

GlyTherix's business model cannot be characterized from the available data. There are no disclosed revenue streams, no funding round history, no named customers or licensing partners, no app or digital product surface, and no certifications or compliance disclosures. The absence of these standard data points means that commercialization pathway, capital structure, and go-to-market mechanics are unknown — a material gap for any investment-grade assessment of an early-stage radiopharmaceutical developer.

Short descriptiontext

GlyTherix Ltd. is a privately held Australian biotechnology company founded in 2017 in Sydney, developing targeted radiotherapy treatments. The firm operates at a small scale (1–10 employees) under CEO Brad Walsh, with no disclosed product pipeline or commercial stage in the available data.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSydney, Australia
HQ citystring
Sydney
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Keyword5 values
targeted radiotherapy, radiopharmaceutical oncology, cancer radioimmunotherapy, antibody radiotherapy, oncology therapeutics
Industry1 code
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Radiopharmaceuticals
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

GlyTherix Ltd. is an Australian targeted radiotherapy company developing targeted radiotherapy treatments. The company focuses on radiotherapy-based approaches for cancer therapy, operating in the radiopharmaceutical/biotech space from its base in Sydney, Australia.

Differentiator
Functional benefit
Problem solved
Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeBroad incumbent
Description

Global pharma with the leading commercial radioligand therapy franchise (Lutathera, Pluvicto). Broad incumbent that defines the commercial benchmark for targeted radiotherapeutics and sets competitive pressure on niche entrants.

TypeBroad incumbent
Description

U.S. radiopharmaceutical-focused company with diagnostic and emerging therapeutic assets (e.g., PNT2002/PNT2003 programmes). Comparable as an established specialty radiopharma operator with both imaging and therapeutic franchises.

TypeRegional player
Description

ASX-listed Australian radiopharmaceutical company developing diagnostic and therapeutic radiopharmaceuticals across oncology. Closely comparable as an Australian-headquartered peer in the same therapeutic and diagnostic radiopharma category.

TypeRegional player
Description

ASX-listed Sydney-based radiopharmaceutical company developing targeted radiopharmaceuticals for oncology. Direct regional peer sharing Australian roots, similar size profile historically, and an overlapping theranostic and targeted radiotherapy thesis.

TypeEmerging player
Description

U.S. clinical-stage company developing radiolabelled therapeutics and oncology drug candidates. Comparable as a smaller, earlier-stage radiotherapeutics developer with a similar need to attract capital or strategic partners.

TypeDirect peer
Description

Clinical-stage radiopharmaceutical company developing actinium-225-based targeted radiotherapeutics for solid tumours (acquired by Bristol Myers Squibb). Direct peer in the targeted radiotherapy category, illustrative of the M&A exit path for such assets.

TypeDirect peer
Description

Clinical-stage developer of targeted alpha therapies (acquired by AstraZeneca). Direct peer in the targeted radiotherapeutics category, with a comparable development-stage platform thesis.

TypeDirect peer
Description

Clinical-stage radiopharmaceutical company developing targeted radioligand therapies for oncology (acquired by Eli Lilly). Direct peer as a focused targeted radiotherapy developer with a comparable asset profile.

TypeBroad incumbent
Description

Diversified pharma with a commercial radiotherapeutic (Xofigo) and active investment in next-generation targeted radionuclide therapies through its Radioligand Therapy platform. Comparable as a broad incumbent in therapeutic radiopharma.

TypeDirect peer
Description

German radiopharmaceutical company developing targeted radionuclide therapies and producing medical radioisotopes. Direct peer in the targeted radiotherapeutics category, with both development pipeline and isotope production capabilities.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GlyTherix Ltd.

Radiopharmaceuticalsglytherix.com

GlyTherix Ltd. is a privately held Australian biotechnology company founded in 2017 in Sydney, developing targeted radiotherapy treatments. The firm operates at a small scale (1–10 employees) under CEO Brad Walsh, with no disclosed product pipeline or commercial stage in the available data.

What GlyTherix Ltd. does

GlyTherix Ltd. is an Australian private biotechnology company focused on targeted radiotherapy, headquartered in Sydney and founded in 2017. The company operates in the radiopharmaceutical space, which typically involves the development of biological targeting agents (such as antibodies or small molecules) conjugated to therapeutic radioisotopes designed to deliver localized radiation to cancer cells while sparing healthy tissue. The firm's strategic positioning is consistent with the broader global shift toward precision oncology and theranostics, though the specific molecular targets, radioisotopes, and indication areas are not disclosed in the available source data.

The company is small-scale, with 1–10 employees per the firmographic data, and operates as a privately held for-profit entity. Brad Walsh is identified as Chief Executive Officer. There is no disclosed product portfolio, pricing model, manufacturing capability, clinical pipeline, regulatory filing status, or partnership structure in the provided inputs. The company website (glytherix.com) was not accessible for content extraction at the time of data collection, which itself limits the verification surface for the company's claims.

GlyTherix's business model cannot be characterized from the available data. There are no disclosed revenue streams, no funding round history, no named customers or licensing partners, no app or digital product surface, and no certifications or compliance disclosures. The absence of these standard data points means that commercialization pathway, capital structure, and go-to-market mechanics are unknown — a material gap for any investment-grade assessment of an early-stage radiopharmaceutical developer.

GlyTherix Ltd. firmographics

Firmographics
Name
GlyTherix Ltd.
Website
https://glytherix.com
Company type
Private
Founded year
2017
Headcount range
1–10 employees
Short description
GlyTherix Ltd. is a privately held Australian biotechnology company founded in 2017 in Sydney, developing targeted radiotherapy treatments. The firm operates at a small scale (1–10 employees) under CEO Brad Walsh, with no disclosed product pipeline or commercial stage in the available data.
Ownership category
akta.pro rank

GlyTherix Ltd. industry classification

Industry
Product category
Radiopharmaceuticals
NAICS
Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Targeted radiotherapy
  • Radiopharmaceutical oncology
  • Cancer radioimmunotherapy
  • Antibody radiotherapy
  • Oncology therapeutics

Where GlyTherix Ltd. is headquartered

Location

Headquarters

HQ city
Sydney
HQ country
Australia
HQ region
Oceania

Markets served

GlyTherix Ltd. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

GlyTherix Ltd. product offering

Product offering

Core offering

GlyTherix Ltd. is an Australian targeted radiotherapy company developing targeted radiotherapy treatments. The company focuses on radiotherapy-based approaches for cancer therapy, operating in the radiopharmaceutical/biotech space from its base in Sydney, Australia.

Differentiator

Problem solved

Functional benefit

Companies that use GlyTherix Ltd.

Customer profile

Ideal customer profiles2 records

GlyTherix Ltd. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

GlyTherix Ltd. partnerships and signals

Strategic signal

Recent moves2 records

GlyTherix Ltd. competitors and assessment

Company assessment

Broad incumbents

  • Novartis: Global pharma with the leading commercial radioligand therapy franchise (Lutathera, Pluvicto). Broad incumbent that defines the commercial benchmark for targeted radiotherapeutics and sets competitive pressure on niche entrants.
  • Lantheus Holdings: U.S. radiopharmaceutical-focused company with diagnostic and emerging therapeutic assets (e.g., PNT2002/PNT2003 programmes). Comparable as an established specialty radiopharma operator with both imaging and therapeutic franchises.
  • Bayer: Diversified pharma with a commercial radiotherapeutic (Xofigo) and active investment in next-generation targeted radionuclide therapies through its Radioligand Therapy platform. Comparable as a broad incumbent in therapeutic radiopharma.

Regional players

  • Telix Pharmaceuticals: ASX-listed Australian radiopharmaceutical company developing diagnostic and therapeutic radiopharmaceuticals across oncology. Closely comparable as an Australian-headquartered peer in the same therapeutic and diagnostic radiopharma category.
  • Clarity Pharmaceuticals: ASX-listed Sydney-based radiopharmaceutical company developing targeted radiopharmaceuticals for oncology. Direct regional peer sharing Australian roots, similar size profile historically, and an overlapping theranostic and targeted radiotherapy thesis.

Emerging players

  • Moleculin Biotech: U.S. clinical-stage company developing radiolabelled therapeutics and oncology drug candidates. Comparable as a smaller, earlier-stage radiotherapeutics developer with a similar need to attract capital or strategic partners.

Direct peers

  • RayzeBio: Clinical-stage radiopharmaceutical company developing actinium-225-based targeted radiotherapeutics for solid tumours (acquired by Bristol Myers Squibb). Direct peer in the targeted radiotherapy category, illustrative of the M&A exit path for such assets.
  • Fusion Pharmaceuticals: Clinical-stage developer of targeted alpha therapies (acquired by AstraZeneca). Direct peer in the targeted radiotherapeutics category, with a comparable development-stage platform thesis.
  • Point Biopharma: Clinical-stage radiopharmaceutical company developing targeted radioligand therapies for oncology (acquired by Eli Lilly). Direct peer as a focused targeted radiotherapy developer with a comparable asset profile.
  • ITM Isotope Technologies Munich: German radiopharmaceutical company developing targeted radionuclide therapies and producing medical radioisotopes. Direct peer in the targeted radiotherapeutics category, with both development pipeline and isotope production capabilities.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

GlyTherix Ltd. social profiles

Digital presence

GlyTherix Ltd. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GlyTherix Ltd. leadership team

Management profile

Number of profiles

Profiles1 record

GlyTherix Ltd. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GlyTherix Ltd. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GlyTherix Ltd.

What does GlyTherix Ltd. do?

GlyTherix Ltd. is an Australian targeted radiotherapy company developing targeted radiotherapy treatments. The company focuses on radiotherapy-based approaches for cancer therapy, operating in the radiopharmaceutical/biotech space from its base in Sydney, Australia.

When was GlyTherix Ltd. founded?

GlyTherix Ltd. was founded in 2017. It employs 1 to 10 people.

Where is GlyTherix Ltd. based?

GlyTherix Ltd. is headquartered in Sydney, Australia, in the Oceania region.

Who are GlyTherix Ltd.'s main competitors?

Broad incumbents on record are Novartis, Lantheus Holdings and Bayer. Regional players are Telix Pharmaceuticals and Clarity Pharmaceuticals. Moleculin Biotech is listed as an emerging player. Direct peers are RayzeBio, Fusion Pharmaceuticals, Point Biopharma and ITM Isotope Technologies Munich.

Does GlyTherix Ltd. have an API?

No public API is recorded for GlyTherix Ltd..

What industry is GlyTherix Ltd. in?

GlyTherix Ltd.'s product category is Radiopharmaceuticals. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy). Its NAICS code is 5417 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals